Impact of Wnt/β-Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• The Wnt signaling pathway regulates cell differentiation and cycle events, with inhibitors like PRI-724 showing efficacy in other cancers.
• Wnt signaling is implicated in soft tissue sarcoma (STS) tumorigenesis, a disease with limited advanced treatment options.

Purpose of the Study:

• To investigate the role of Wnt/β-catenin signaling in STS.
• To evaluate the efficacy of Wnt inhibition using PRI-724 in STS cell lines and primary cultures.
• To explore PRI-724 as a potential combination therapy for advanced STS.

Main Methods:

• Treatment of STS cell lines and primary cultures with PRI-724.
• Assessment of cell viability, proliferation, and death rates.
• Analysis of TCF/β-catenin transcriptional activity and target gene expression (CCND1, CDC25A).
• siRNA-mediated downregulation of CDC25A.
• Evaluation of NCBI/GenBank data for CDC25A mRNA levels in STS patients.
• Combination studies with doxorubicin or trabectedin, analyzed using isobolographic analysis.

Main Results:

• PRI-724 suppressed STS cell viability and proliferation while increasing cell death.
• TCF/β-catenin transcriptional activity and target genes CCND1 and CDC25A were downregulated.
• siRNA-mediated CDC25A downregulation mimicked PRI-724's effects on cell cycle arrest and cell death.
• Elevated CDC25A mRNA levels were confirmed in STS patients.
• PRI-724 synergistically enhanced the antitumoral effects of doxorubicin and trabectedin.

Conclusions:

• Wnt/β-catenin signaling inhibition via PRI-724 demonstrates significant antitumoral activity in STS.
• Downregulation of CDC25A is a key mechanism underlying PRI-724's efficacy.
• PRI-724 represents a promising therapeutic strategy, particularly in combination with standard chemotherapeutics, for advanced STS.